Skip to main content
. 2022 Mar 25;88(8):3674–3682. doi: 10.1111/bcp.15310

FIGURE 1.

FIGURE 1

Model schematic for tenofovir disoproxil fumarate and emtricitabine disposition. ka, absorption rate constant; ALAG, lag time; CL, clearance from the central compartment; V2, central compartment volume of distribution; V4, peripheral compartment volume of distribution; Q1, intercompartmental clearance; K23, formation rate constant of metabolite stimulated by plasma drug; K30, elimination rate constant of intracellular metabolite